Core Viewpoint - The company, Harbin Fuirjia Technology Co., Ltd., is committed to enhancing its quality and investor returns through a "Quality and Return Improvement" action plan, aligning with national policies to boost capital market activity and investor confidence [1] Group 1: Business Focus and Innovation - The company focuses on its core business, aiming to enhance innovation capabilities and core competitiveness, with a vision of showcasing "Chinese beauty to the world" [1] - During the reporting period, the company achieved a net profit attributable to shareholders of 166,174,897.97 yuan after deducting non-recurring gains and losses [1] - The company has launched several new products in response to market demand, including medical and functional skincare products [2] Group 2: Investor Returns - The company emphasizes investor returns by adhering to legal regulations regarding profit distribution and actively engaging with investors [3] - In the 2024 annual shareholders' meeting, the company approved a profit distribution plan, distributing 10 yuan per 10 shares in cash dividends and increasing capital by 3 shares for every 10 shares held [3] Group 3: Corporate Governance - The company has established a clear governance structure, complying with relevant laws and regulations to ensure effective operation and stability [3][4] - The company appointed a new assistant general manager to further enhance its governance structure [4] Group 4: Information Disclosure and Investor Relations - The company prioritizes high-quality information disclosure, ensuring compliance with legal requirements and enhancing transparency for investors [5][6] - A diversified investor communication mechanism has been established, including various platforms for interaction, to deepen investor understanding and trust [5][6] - The company actively engages with investors through multiple channels, ensuring timely responses to inquiries and suggestions [5][6]

Core Insights - Fulejia showcased its advanced skincare technology and innovative products at the 5th China International Consumer Products Expo, emphasizing its commitment to high-end medical skincare and global brand expansion [1] - The global launch of Sculptra, an injectable poly-L-lactic acid filler, in China marks a significant milestone, as it is the first of its kind approved by both the FDA and the EU, with over 25 years of safety and clinical evidence [1] Industry Summary - The skincare industry is evolving towards more technological and professional solutions, driven by increasing consumer demand for safe and effective products [2] - The market is expected to see strong growth from companies with comprehensive brand matrices and product categories, such as Marubi Biotechnology [2] - Companies like Juzi Biotechnology are poised for rapid development by accurately targeting niche markets, particularly with the rise of collagen reorganization and domestic beauty trends [2] - Betaini is leveraging high cost-performance and strong product innovation to capture market share [2] - Longzi Co. is focusing on both external expansion and internal growth strategies in the medical aesthetics sector, indicating significant future potential [2] - East China Pharmaceutical is demonstrating strong development potential through its innovative drug research and medical aesthetics product pipeline [2]